Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| University of Washington Department of Laboratory Medicine, |
RCV000758616 | SCV000887373 | likely benign | Lynch syndrome | 2018-05-01 | criteria provided, single submitter | clinical testing | MSH6 NM_000179.2:c.3964G>A has a 1.8% probability of pathogenicity based on combining prior probability from public data with a likelihood ratio of 0.16 to 1, generated from evidence of seeing this as a somatic mutation in a tumor with loss of heterozygosity at the MSH6 locus. See Shirts et al 2018, PMID 29887214. |
| Ambry Genetics | RCV001021540 | SCV001183167 | uncertain significance | Hereditary cancer-predisposing syndrome | 2022-12-08 | criteria provided, single submitter | clinical testing | The p.E1322K variant (also known as c.3964G>A), located in coding exon 9 of the MSH6 gene, results from a G to A substitution at nucleotide position 3964. The glutamic acid at codon 1322 is replaced by lysine, an amino acid with similar properties. Using a Bayesian analysis that incorporates tumor mutation data, this variant was classified as likely benign (Shirts BH et al. Am J Hum Genet, 2018 Jul;103:19-29). In an in vitro complementation assay using MSH6 deficient nuclear extracts from cells, this variant was shown to be functional (Drost M et al. Genet Med, 2020 May;22:847-856). This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |